The second most common cause of death worldwide is cancer - with liver cancer being the second most common cause of death from cancer. Accounting for some 90% of all liver cancers,Hepatocellular carcinoma (HCC) is the most common type of liver cancer - with tthe typical survival rates being only 6 -20 months. Therabionic is focused on the commercialization of its first oncology application: specifically treatment of advanced hepatocellular carcinoma. The firm's Phase II study is completed - showing effectiveness as well as excellent tolerability, even in previously treated patients with severely impaired liver function. The firm has also employed a targeted therapy using non-thermal radio waves improved overall survival in hepatocellular carcinoma (HCC) patients - that a recent study indicated as having had no side effects, a new study found. The study, published online in 4Open, Wake Forest School of Medicine researchers utilized TheraBionic P1, --s a hand-held device that emits radio frequencies via a spoon-shaped antenna that is placed on the patientÂ’s tongue and delivers low levels of radiofrequency electromagnetic fields throughout their body. The TheraBionic device, having in 2019 received Breakthrough Devices Designation from the Food and Drug Administrationis currently under evaluation and is not yet in commercial use.
